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D

ata sharing has incredible potential to
strengthen academic research, the practice
of medicine, and the integrity of the clinical trial system. Some benefits are obvious: when

researchers have access to complete data, they can answer new
questions, explore different lines
of analysis, and more efficiently
conduct large-scale analyses across
trials. Other advantages, such as
providing a guardrail against
conflicts of interest in a clinical
trial system in which external
sponsorship of research is common and necessary, are less visible yet just as critical.
I appreciate that there are many
policy, privacy, and practical issues that need to be addressed in
order to make data sharing practical and useful for the research
community, but the stakes are
too high to step back in the face
of that challenge.
One policy proposal that I am

particularly enthusiastic about is
making data sharing a condition
of publication in major medical
journals. In a recent letter to the
International Committee of Medical Journal Editors (ICMJE), I applauded the committee’s work in
developing a framework for data
sharing.1 The ICMJE’s proposal
would require that, as a condition
of having their research manuscripts considered for publication,
authors share the deidentified
patient data on which their results
are based. This requirement would
be a significant step forward in
improving the transparency of
clinical trials for consumers and
the academic medical community.
Although the privacy of participants must be protected, access
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to the data underlying trial results
can provide an avenue for independent confirmation of results
and further analyses of the data
set, raising the bar for academic
rigor and integrity and speeding
the progress of medical research.
As I told the members of the
ICMJE, I believe that linking data
sharing with publication can also
help address the patchwork landscape of current regulations related to the sharing of clinical trial
data. Because regulatory agencies
have different protocols and requirements for sharing data related to the drugs and devices they
approve, access to data about a
clinical trial often hinges on which
agency handles a regulatory submission rather than on the value
of these data to consumers and
researchers. By requiring data
sharing as a condition of publication, journals can help synchronize and expand existing datasharing practices.
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I am also encouraged by the
potential of such proposals to
improve compliance with existing laws and regulations related
to the reporting of clinical trial
results. Each of the several ongoing efforts to increase data sharing
through other routes has faced
unique challenges. U.S. law has
required the posting of summary
clinical trial research results to
the ClinicalTrials.gov database
since the adoption of the Food
and Drug Administration Amendment Act (FDAAA) in 2007. However, recent analyses have highlighted variation across sectors
when it comes to trial sponsors’
compliance with this law, in part
due to a lack of final regulations,
which leaves uncertainty about
standards and impedes the ability
of federal agencies to enforce requirements.2-4 The European Medicines Agency has developed a
policy that would require patientlevel data to be disclosed after a
drug has been approved. This
plan has been delayed because of
disagreement among stakeholders about how to share these
data. Compliance with the more
rigorous ICMJE requirements,
though it will not automatically
harmonize existing regulations,
could nonetheless create a baseline expectation that data will be
shared and prepare researchers
to comply with other mandates.
Requiring researchers to file a
data-sharing plan for patient-level
data when they initially register a
trial could increase pressure on
trial sponsors to post results in a
timely fashion, regardless of the
type of trial, the country of origin of the research, and whether
or not the research is being performed to support approval of a
new medical product.
The costs associated with pre-
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paring data for sharing can and
should be built into the grants,
cooperative agreements, and contracts that researchers negotiate
with trial sponsors; in other
words, expenses associated with
administering data-sharing protocols must be treated as a standard, necessary aspect of the
costs of carrying out a clinical
trial. And over the long run, data
sharing may help reduce costs
by allowing researchers to avoid
duplicating trials or to answer
questions without undertaking a
separate data-collection effort.
Widespread practices of data
sharing can also help to address
concerns about conflicts of interest that may arise when clinical
trials are funded by industry
sponsors that stand to profit
from favorable research results.
By making trial results available
for independent scrutiny by outside reviewers, data sharing makes
it less likely that trial sponsors
can buy the analysis and results
they want. Expanding opportunities for scrutiny through data
transparency raises the bar for
integrity in analysis and interpretation of results, helping to improve the reproducibility and rigor
of our clinical trial system.
As the research community
and policymakers develop and
implement data-sharing requirements, I urge them to craft clear
standards for granting qualified
researchers access to the data
underlying published results in
cases in which the data cannot
be made public. I recognize that
some types of data may necessitate additional protections to preserve the rights and privacy of
trial participants and researchers.
However, these protections should
not place undue burdens on researchers or restrict data access
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to an overly narrow pool of researchers, nor should they be
used to shield data from public
view when no legitimate justification exists for restricting public access.
I understand the trepidation
that some academics in medical
research feel when they contemplate publicly sharing data. As an
academic myself, I know the professional stakes attached to credit
for original research. I expect
that the field will engage in vigorous debate over what length of
delay is appropriate before individual-level patient data are released publicly. However, I urge
researchers with concerns about
academic credit or a new way of
doing things not to lose sight
of the bigger picture: transparency and reanalysis of data are
core practices of rigorous, peerreviewed research, and increasing access to data will ultimately
strengthen — rather than erode
— these practices.
Finally, in considering how to
encourage data sharing, I urge
members of the medical research
community to also consider ways
to improve the public sharing of
information from trials that have
produced null, inconclusive, or
negative results. As a recent study
emphasized, negative trial results
have a “sizeable scientific impact,” yet they are less likely to
find their way into the pages of
major medical journals.5 Encouraging the publication of such
trials and the release of their
underlying data will help to further accelerate medical progress,
uphold the ethical standards of
human-subjects research, and help
in holding industry sponsors accountable.
Data sharing holds incredible
promise for strengthening the
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practice of medical research and
the integrity of our clinical trial
system. I look forward to following these proposals as they continue to develop and urging their
implementation.
Disclosure forms provided by the author
are available at NEJM.org.
Elizabeth Warren (D-MA) is a U.S. senator.
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A

clinician researcher has an
idea for a study that could
change practice. The researcher
identifies an existing data set
that is ideal for her study — other
researchers conducted a clinical
trial, produced this data set, and
published a report of the primary
findings. Time has passed since
the initial publication, and the
data are not being used. But this
clinical investigator may not be
able to pursue her question, since
data from clinical trials are often
not shared, and researchers may
be discouraged from working
with clinical trial data they did
not generate themselves.
The experience of clinical researchers differs markedly from
that of many physicists, astronomers, and geneticists, who actively share data from resources such
as the Large Hadron Collider, the
Hubble Space Telescope, and the
Human Genome Project. Various
leaders and organizations are now
pushing for medical research to
change in this regard. Vice President Joe Biden has made data
sharing an essential feature of
the cancer “moonshot.” Private-

and public-sector research funders
are developing clear expectations
for sharing data from the work
they support. For example, in
2015 the National Institutes of
Health made explicit its intent to
make public the digital data from
its funded studies. The pharmaceutical industry has articulated
principles that support data sharing, and many companies have
implemented programs to make
their data assets available. Regulatory agencies, most notably the
European Medicines Agency, are
requiring greater sharing by companies seeking to market drugs
and devices, and influential organizations such as the World
Health Organization and the National Academy of Medicine have
released reports calling for responsible sharing of clinical trial
data.1 Notably, the policy of the
Bill and Melinda Gates Foundation is that the data underlying
published results be made available and open immediately.
Amid this activity, the International Committee of Medical
Journal Editors (ICMJE) stepped
forward with a proposal to accel-
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erate the transformation to a culture of open science.2 The ICMJE
asserted its belief that data owners have “an ethical obligation to
responsibly share data generated
by interventional clinical trials.”
The committee proposed requiring authors to make deidentified
individual-participant data underlying the results in a published
report from a clinical trial available for sharing no more than
6 months after publication — a
slightly more permissive policy
than that of the Gates Foundation. It has also proposed that
authors prospectively include a
plan for data sharing as part of
the registration of clinical trials.
The ICMJE proposal has the potential to spur the transformation of the research culture so
that data sharing becomes the
norm. Indeed, if properly implemented, the proposal could promote a culture that maximizes
the contributions of patients who
volunteer to participate in clinical trials.
This proposal is not the first
time that the ICMJE has used its
influence to improve the clinical
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